Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut de Recherches Internationales Servier
With
ADIR, a Servier Group company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Women or men aged \>/=18 years
Patients with a measurable histologically confirmed Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL) and Marginal Zone Lymphoma (MZL) (Arm A), or patients with an evaluable immunophenotypically confirmed CLL (Arm B), or patients with a measurable Multiple Myeloma t(11;14) (arm A expansion part) according to International Myeloma Working Group (IMWG) criteria
Relapsed after or refractory disease to standard treatments, and require treatment in the opinion of the investigator
Estimated life expectancy \> 12 weeks
World Health Organization (WHO) performance status 0-2
Adequate bone marrow, renal and hepatic functions
No evidence or treatment for another malignancy within 2 years prior to study entry. Curatively treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia is allowed
B-cell NHL patients at low risk of tumour lysis syndrome (TLS)
Recent/concomitant treatment altering gastric pH
You may not be if
Previous treatment with a BH3 mimetic
Previous therapy for the studied disease within 3 weeks before first intake
Radioimmunotherapy, radiotherapy within 8 weeks before first intake
Major surgery within 3 weeks before first day of study drug dosing
Corticosteroids \>= 20 mg prednisone equivalent per day within 7 days before first intake
Anticoagulant oral drugs, aspirin \> 325 mg/day within 7 days prior to first S 55746 intake
Positive direct antiglobulin test (Coombs test) and haptoglobin below normal value
Prior allogenic stem cell transplant
Autologous stem cell transplant within 3 months before first intake
NHL patients diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukaemia
Human immunodeficiency virus (HIV)
Known acute or chronic hepatitis B or hepatitis C
Impaired cardiac function
Medications known to prolong corrected QT (QTc) interval
History or/ clinically suspicious for cancer- related Central Nervous System disease
Solitary extramedullary plasmacytoma
Laboratory Signs of TLS
Strong or moderate CYP3A4 inhibitors/inducers (treatment, food or drink products)
Treatment highly metabolized by the CYP3A4 or CYP2D6 and/or substrates with a narrow therapeutic index, multienzyme and/or OATP and/or P-gp substrates or herbal products.
Known hypersensitivity to rasburicase
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolytic anaemia
Patients receiving proton pump inhibitor
Clareo Health | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
